Ovarian cancer

An in-depth report on the causes, diagnosis, treatment, and prevention of ovarian cancer.

I Would Like to Learn About:

Related Reports

References

American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol. 2011;117(3):742-746. PMID: 21343791 www.ncbi.nlm.nih.gov/pubmed/21343791.

Coleman RL, Liu J, Matsuo K, Thaker PH, Westin SN, Sood AK. Carcinoma of the ovaries and fallopian tubes. In: Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE, eds. Abeloff's Clinical Oncology. 6th ed. Philadelphia, PA: Elsevier; 2020:chap 86.

Coleman RL, Ramirez PT, Gershenson DM. Neoplastic diseases of the ovary: screening, benign and malignant epithelial and germ cell neoplasms, sex-cord stromal tumors. In: Lobo RA, Gershenson DM, Lentz GM, Valea FA, eds. Comprehensive Gynecology. 7th ed. Philadelphia, PA: Elsevier; 2017:chap 33.

Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17-38. PMID: 29249039 www.ncbi.nlm.nih.gov/pubmed/29249039.

Doubeni CA, Doubeni AR, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Physician. 2016;93(11):937-944. PMID: 27281838 www.ncbi.nlm.nih.gov/pubmed/27281838.

Finch AP, Lubinski J, Møller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547-1553. PMID: 24567435 www.ncbi.nlm.nih.gov/pubmed/24567435.

Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;319(6):595-606. PMID: 29450530 www.ncbi.nlm.nih.gov/pubmed/29450530.

Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240-1253. PMID: 30910306 www.ncbi.nlm.nih.gov/pubmed/30910306.

Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500-2510. PMID: 23715580 www.ncbi.nlm.nih.gov/pubmed/23715580.

Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812-822. PMID: 23628597 www.ncbi.nlm.nih.gov/pubmed/23628597.

Moyer VA; U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(4):271-281. PMID: 24366376 www.ncbi.nlm.nih.gov/pubmed/24366376.

National Cancer Institute website. Ovarian, fallopian tube, and primary peritoneal cancer prevention (PDQ) - health professional version. www.cancer.gov/types/ovarian/hp/ovarian-prevention-pdq. Updated December 13, 2019. Accessed December 27, 2019.

National Comprehensive Cancer Network website. Genetic/Familial High-Risk Assessment: Breast and Ovarian.Version 3.2019. www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf. Updated January 18, 2019. Accessed June 20, 2019.

National Comprehensive Cancer Network website. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer.Version 1.2019. www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf. Updated March 8, 2019. Accessed June 20, 2019.

Neff RT, Senter L, Salani R. BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol. 2017;9(8):519-531. PMID: 28794804 www.ncbi.nlm.nih.gov/pubmed/28794804.

Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284-296. PMID: 29809280 www.ncbi.nlm.nih.gov/pubmed/29809280.

BACK TO TOP

Review Date: 8/26/2019  

Reviewed By: Howard Goodman, MD, Gynecologic Oncology, Florida Cancer Specialists & Research Institute, West Palm Beach, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

ADAM Quality Logo

A.D.A.M., Inc. is accredited by URAC, for Health Content Provider (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics. This site complies with the HONcode standard for trustworthy health information: verify here.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2022 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

A.D.A.M. content is best viewed in IE9 or above, Firefox and Google Chrome browser.